Study summary

Tarlatamab beat chemotherapy after first treatment

DeLLphi-304 trial · 509 people, phase 3 · Published June 2025, New England Journal of Medicine; full FDA approval November 2025

13.6 momedian survival with tarlatamab, vs 8.3 with chemotherapy

What was tested

Tarlatamab against standard chemotherapy for small cell lung cancer that grew after platinum chemotherapy.

What they found

Median survival was 13.6 vs 8.3 months.
Serious side effects were less common than with chemotherapy (54% vs 80%).

What it means

Established tarlatamab as the second-line standard.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.